However, their PBPK model failed to predict atomoxetine disposition in 100% of East Asian populations with CYP2D6 EM or CYP2D6*10/*10 genotypes or phenotypes, drug interaction studies, and specific population with renal disease or hepatic impairment. This evidence concerns the gene CYP2D6 and kidney disorder.